Teleflex reported Q1 2026 on May 7 with revenue up 32.3% on a GAAP basis to $548.3 million, the Interventional segment up 3% to $204.7 million, and adjusted gross margin down 470 basis points to 61.4% on tariffs, quality remediation charges, higher logistics costs, and product mix from the recently absorbed Vascular Intervention acquisition. The 2026 guidance carries a $33 million tariff headwind. Penumbra reported $374.8 million on May 6, up 15.6%, with the Boston Scientific merger close pending and no full-year guidance issued. Profound Medical and Sight Sciences both posted Q1 results that lift FY26 expectations on the interventional MRI and interventional eye care platforms. Read across the four reports, the picture is consistent. Interventional medtech topline growth is real, and the margin tax underneath the topline that founders building the next generation of advanced interventional platforms have to plan for is now a structural feature of the segment.
Teleflex Q1: 32% Topline, 470 Basis Points of Margin Compression
Teleflex reported first quarter revenue of $548.3 million on May 7, an increase of 32.3% on a GAAP basis and 5.1% on a pro forma adjusted constant currency basis year over year. The Interventional segment generated $204.7 million in revenue, a 3% rise year over year, supported by intraosseous, right heart, and complex catheters. The headline growth carries a substantial cost line underneath. Adjusted gross margin declined 470 basis points to 61.4% year over year, with management attributing the compression to tariffs, quality remediation charges, higher logistics costs, and product mix from the Vascular Intervention acquisition. Adjusted operating margin fell 510 basis points, pressured by the gross margin decline and operating expenses linked to the recent acquisition and higher R&D spend. Adjusted EPS came in at $1.39, a 3.5% decrease year over year. Tariffs alone represent a $33 million headwind in the 2026 guidance, with potential refunds for 2025 or 2026 payments treated as upside rather than baseline.
For founders building advanced interventional platforms, the Teleflex Q1 read is the cleanest current data point on what the integration economics actually look like when the topline arrives via M&A and the cost lines underneath the integration absorb tariffs, quality remediation, and logistics simultaneously. The Vascular Intervention acquisition delivered the topline that produced the 32.3% GAAP growth, and the cost lines underneath the acquired business produced the margin compression that put adjusted EPS down year over year. The structural read is that interventional M&A on the Teleflex scale absorbs a multi-quarter integration tax even when the strategic logic of the deal is sound, and the 2026 guidance now has to absorb the tariff line on top of the integration line. Founders preparing for a strategic conversation with the Teleflex-class acquirers in the second half of 2026 should price the integration math the buyer is actually running, not the topline math that gets quoted in the press release.
Penumbra Q1: 15.6% Growth Into the Boston Scientific Close
Penumbra reported Q1 2026 revenue of $374.8 million on May 6, up 15.6% year over year, with thrombectomy revenue of $253.9 million up 12.1% and embolization and access revenue of $120.8 million up 23.8%. Gross margin held at 67.6%. Operating expenses were $215.2 million, including $9.4 million of acquisition-related expenses tied to the pending Boston Scientific transaction. The company is not providing full-year 2026 guidance and will not host an earnings call, given the pending Boston Scientific acquisition at $374 per share, valuing the transaction at approximately $14.5 billion with consideration mix targeted at roughly 73% cash and 27% Boston Scientific stock, subject to shareholder and regulatory approvals.
The Penumbra Q1 print confirms what the Boston Scientific strategic logic depends on. The thrombectomy and embolization franchises are still growing through the merger announcement window, the gross margin profile is intact, and the only material new cost line on the income statement is the acquisition-related expense tied to closing the deal. The structural read for founders is that the strategic acquirer is paying $14.5 billion for a clean platform that delivers double-digit growth across two segments with a 67.6% gross margin, and the platform is being absorbed without margin damage to the underlying franchise. The platforms that arrive at the strategic conversation with the Penumbra-class operating profile get the Penumbra-class multiple. The platforms that arrive with margin damage from integration absorption get priced against the Teleflex-class profile instead.
Profound Medical and Sight Sciences: Specialist Interventional Q1 Strength
Profound Medical reported Q1 2026 results on May 7, with the company describing triple-digit revenue growth combined with strong gross margin and lower operating expenses, and projecting full-year 2026 revenue of approximately $25 million, representing 56% growth over the prior year. The TULSA-PRO interventional MRI platform anchors the growth profile, and the operating expense discipline produced gross margin expansion against the prior period. Sight Sciences reported Q1 revenue of $19.7 million on May 7, up 13% year over year, with gross margin at 86% and growth across both interventional segments. The company raised full-year 2026 revenue guidance to $83 million to $89 million on the strength of the reimbursed dry eye business and steady glaucoma execution.
The two specialist interventional reports describe the operating posture that produces multiple-expansion outcomes in the current environment. Profound Medical is delivering category-defining growth on a focused interventional MRI platform with operating expense discipline that compounds through the year. Sight Sciences is delivering 13% growth at 86% gross margin with raised full-year guidance against a reimbursement structure that the operating plan has worked through. Neither company is absorbing the integration tax that compressed Teleflex’s adjusted gross margin by 470 basis points, and the operating profile each is producing matches the cleared-platform commercial template strategic acquirers are paying premiums for in the second-half 2026 conversation. The operating discipline that protects gross margin through the growth phase is the discipline that produces the multiple at the strategic conversation.
What the Q1 Reports Mean for the Founder Operating Plan
Read together, the four Q1 reports describe the structural choice every advanced interventional founder is now making in real time. Teleflex grew 32.3% on M&A absorption and lost 470 basis points of adjusted gross margin underneath the topline. Penumbra grew 15.6% organically into a $14.5 billion strategic acquisition with no margin damage. Profound Medical and Sight Sciences are growing on specialist platforms with gross margin discipline that lifts the operating profile through the year. The strategic acquirers in the second half of 2026 are reading these four operating profiles side by side and pricing the platforms that protect gross margin through growth at premiums to the platforms that absorb the integration and tariff tax through the operating line.
For founders building the next generation of advanced interventional platforms, the operating plan question is how the gross margin profile and the cost line architecture will look at the moment the platform reaches commercial scale. The platforms that produce category-defining topline growth on cost structures that absorb tariffs, integration, and logistics through the gross margin line arrive at the strategic conversation at the Teleflex-class multiple. The platforms that produce double-digit growth on gross margins above 65% with operating expense discipline that compounds through the year arrive at the Penumbra-class or Sight Sciences-class multiple. The Q1 2026 cycle is the cleanest current evidence the segment has produced of which operating profiles the strategic-acquirer evaluation is actually pricing, and the founders running operating plans against those profiles now are the ones positioning the company for the second-half 2026 strategic conversation.
Dave’s take
Topline growth covers a lot of operating sins until the moment a strategic buyer reads the gross margin line. The Teleflex Q1 print shows what happens when integration, tariffs, and quality remediation hit the cost structure at the same time the acquired topline is producing the GAAP growth headline. The founders I am working with this quarter are running the same exercise on their own operating plans. Where does the gross margin profile actually sit at commercial scale, and which cost lines are absorbing the visible growth before it reaches operating income?
I’m here to help you scale.
Work With Dave